Dysregulated signaling hubs of liver lipid metabolism reveal hepatocellular carcinoma pathogenesis
暂无分享,去创建一个
Jens Nielsen | Cheng Zhang | Doheon Lee | Sunjae Lee | Adil Mardinoglu | J. Nielsen | Doheon Lee | A. Mardinoğlu | Sunjae Lee | Cheng Zhang
[1] Andreas Zell,et al. JSBML: a flexible Java library for working with SBML , 2011, Bioinform..
[2] G. Hong,et al. Nucleic Acids Research , 2015, Nucleic Acids Research.
[3] M. Stoffel,et al. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes , 2004, Nature.
[4] Gábor Csárdi,et al. The igraph software package for complex network research , 2006 .
[5] Charity W. Law,et al. voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.
[6] Simo V. Zhang,et al. A map of human cancer signaling , 2007, Molecular systems biology.
[7] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[8] Sahil Mittal,et al. Epidemiology of hepatocellular carcinoma: consider the population. , 2013, Journal of clinical gastroenterology.
[9] Henning Hermjakob,et al. The Reactome pathway Knowledgebase , 2015, Nucleic acids research.
[10] Doheon Lee,et al. Anomalies in Network Bridges Involved in Bile Acid Metabolism Predict Outcomes of Colorectal Cancer Patients , 2014, PloS one.
[11] Z. Bar-Joseph,et al. Linking the signaling cascades and dynamic regulatory networks controlling stress responses , 2013, Genome research.
[12] Michael G. Rosenfeld,et al. Controlling nuclear receptors: the circular logic of cofactor cycles , 2005, Nature Reviews Molecular Cell Biology.
[13] Kenneth H. Buetow,et al. PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..
[14] Gary D. Bader,et al. Using Biological Pathway Data with Paxtools , 2013, PLoS Comput. Biol..
[15] W. Wahli,et al. Sex differences in nuclear receptor-regulated liver metabolic pathways. , 2011, Biochimica et biophysica acta.
[16] R. DuBois,et al. Eicosanoids and cancer , 2010, Nature Reviews Cancer.
[17] Margaret S. Wu,et al. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes , 2011, Proceedings of the National Academy of Sciences.
[18] A. Diehl,et al. NAFLD, NASH and liver cancer , 2013, Nature Reviews Gastroenterology &Hepatology.
[19] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.
[20] M. Sani,et al. Lipid-lowering drugs. , 2004, Nursing older people.
[21] Sandhya Rani,et al. Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..
[22] H. M. Reis,et al. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma , 2013, Nature Reviews Cancer.
[23] D. Hardie,et al. AMPK: a nutrient and energy sensor that maintains energy homeostasis , 2012, Nature Reviews Molecular Cell Biology.
[24] Martin Kuiper,et al. BiNGO: a Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological Networks , 2005, Bioinform..
[25] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[26] Michael J Thun,et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.
[27] K. Tsai,et al. TAp63 is a master transcriptional regulator of lipid and glucose metabolism. , 2012, Cell metabolism.
[28] Karin Dahlman-Wright,et al. Liver X receptor in cholesterol metabolism. , 2010, Journal of Endocrinology.
[29] J. M. Suh,et al. PPARγ signaling and metabolism: the good, the bad and the future , 2013, Nature Medicine.
[30] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[31] I. Nookaew,et al. Integration of clinical data with a genome-scale metabolic model of the human adipocyte , 2013, Molecular systems biology.
[32] J. Pekow,et al. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C‐related cirrhosis , 2007, Cancer.
[33] M. Murad,et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. , 2013, Gastroenterology.
[34] Guido Gerken,et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. , 2012, Journal of hepatology.
[35] Ronald A. DePinho,et al. Hepatocellular carcinoma pathogenesis: from genes to environment , 2006, Nature Reviews Cancer.
[36] Peter Tontonoz,et al. Liver X receptors in lipid metabolism: opportunities for drug discovery , 2014, Nature Reviews Drug Discovery.
[37] Johan Auwerx,et al. Targeting bile-acid signalling for metabolic diseases , 2008, Nature Reviews Drug Discovery.
[38] G. von Heijne,et al. Tissue-based map of the human proteome , 2015, Science.
[39] M. Stoffel,et al. Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. , 2006, Cell metabolism.
[40] Anushya Muruganujan,et al. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees , 2012, Nucleic Acids Res..
[41] W. Huber,et al. which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .
[42] Hans-Werner Mewes,et al. CORUM: the comprehensive resource of mammalian protein complexes , 2007, Nucleic Acids Res..
[43] M. Uhlén,et al. Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease , 2014, Nature Communications.
[44] D. Calvisi,et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. , 2011, Gastroenterology.
[45] A. Dobrzyń,et al. Stearoyl‐CoA desaturase as a new drug target for obesity treatment , 2005, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[46] Réka Albert,et al. Elementary signaling modes predict the essentiality of signal transduction network components , 2011, BMC Systems Biology.
[47] Jerrold M. Ward,et al. Hepatocyte Nuclear Factor 4α (Nuclear Receptor 2A1) Is Essential for Maintenance of Hepatic Gene Expression and Lipid Homeostasis , 2001, Molecular and Cellular Biology.
[48] Gary D Bader,et al. BioPAX – A community standard for pathway data sharing , 2010, Nature Biotechnology.
[49] Bin Zhang,et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..
[50] Peng Qiu,et al. TCGA-Assembler: open-source software for retrieving and processing TCGA data , 2014, Nature Methods.
[51] David B. Berry,et al. Pathway connectivity and signaling coordination in the yeast stress-activated signaling network , 2014, Molecular systems biology.
[52] J. Dufour,et al. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. , 2011, Cancer research.
[53] Henning Hermjakob,et al. The Reactome pathway knowledgebase , 2013, Nucleic Acids Res..
[54] H. J. Lin,et al. The ether lipid tumour marker in human liver with hepatocellular carcinoma. , 1980, British Journal of Cancer.
[55] C. Byrne. Fatty liver: role of inflammation and fatty acid nutrition. , 2010, Prostaglandins, leukotrienes, and essential fatty acids.
[56] O. Boss,et al. GLUT4 glucose transporter deficiency increases hepatic lipid production and peripheral lipid utilization. , 2004, The Journal of clinical investigation.
[57] Damian Smedley,et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data , 2014, Nucleic Acids Res..
[58] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[59] F. Basile,et al. Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma , 2011, Indian Journal of Medical and Paediatric Oncology.
[60] Joseph L Goldstein,et al. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.
[61] W. Wahli,et al. PPARs at the crossroads of lipid signaling and inflammation , 2012, Trends in Endocrinology & Metabolism.